Clinical trial ERA-223
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
| Cancers | |
|---|---|
| Organ | prostate |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Bayer |
| EudraCT Identifier | 2013-003438-33 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02043678 |
| Inclusion criteria | *Histologically confirmed adenocarcinoma of the prostate*Prostate cancer progression documented by PSA according to the Prostate CancerWorking Group 2 (PCWG2) criteria or radiological progressionaccording to RECIST, version 1.1*Two or more bone meta |
| Last update |